Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung der ADHS im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Cortese S, Moreira-Maia CR, St Fleur D et al (2016) Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry 173(1): 34–43
Dalsgaard S, Kvist AP, Leckman JF et al (2014) Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol 24(6): 302–310
Hart H, Radua J, Nakao T et al (2013) Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. JAMA Psychiatry 70(2): 185–198
Hechtman L, Greenfield B (2003) Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr Drugs 5(12): 787–974
Ji N, Findling RL (2015) An update of pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry 28(2): 91–101
Kratochvil C (2012) ADHD pharmacotherapy: rates of stimulant use and cardiovaskular risk. Am J Psychiatry 169(2): 112–114
Linderkamp F, Lauth G (2011) Zur Wirksamkeit pharmakologischer und psychotherapeutischer Therapien bei Aufmerksamkeitsdefizit-/Hyperaktivitätsstörungen (ADHS) im Erwachsenenalter: Eine empirische Metanalyse. Verhaltenstherapie 21: 229–238
Moffitt TE, Houts R, Asherson P et al (2015) Is adult ADHD a childhood neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry 172(10): 967–977
NICE Clinical Guideline 72 (2008, aktualisiert 2013) Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. www.guidance.nice.org/cg72
Normann C, Berger M (2008) Neuroenhancement: status quo and perspectives. Eur Arch Psychiatry Clin Neuroscience 258(Suppl 5): 110–114
Perugi G, Vannucchi G (2015) The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder. Expert Opin Pharmacother 16(14): 2193–2204
Prada P, Nicastro R, Zimmermann J et al (2015) Addition to methylphenidate to intensive dialectical behavior therapy for patients suffering from comorbid borderline personality disorder and ADHD: a naturlastic study. Atten Defic Hyperact Disord 7(3): 199–209
Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM (2008) Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 28(5): 793–800
Vitiello B, Elliott GR, Swanson JM et al (2012) Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry 169: 167–177
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Heiser, P., Benkert, O. (2017). Medikamente zur Behandlung von ADHS und anderen Entwicklungsstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50333-1_10
Download citation
DOI: https://doi.org/10.1007/978-3-662-50333-1_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-50332-4
Online ISBN: 978-3-662-50333-1
eBook Packages: Medicine (German Language)